

# Wang Fusheng

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/6244667/wang-fusheng-publications-by-year.pdf>

**Version:** 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

52 papers	10,502 citations	25 h-index	61 g-index
61 ext. papers	13,743 ext. citations	15.1 avg, IF	7.06 L-index

#	Paper	IF	Citations
52	Characterization and Distribution of HIV-infected Cells in Semen.. <i>Emerging Microbes and Infections</i> , <b>2022</b> , 1-40	18.9	
51	Mesenchymal stem cell treatment for COVID-19.. <i>EBioMedicine</i> , <b>2022</b> , 77, 103920	8.8	2
50	Global transcriptomic characterization of T cells in individuals with chronic HIV-1 infection.. <i>Cell Discovery</i> , <b>2022</b> , 8, 29	22.3	3
49	Implications of the accumulation of CXCR5 NK cells in lymph nodes of HIV-1 infected patients.. <i>EBioMedicine</i> , <b>2021</b> , 75, 103794	8.8	1
48	Immune Dysfunctions of CD56 NK Cells Are Associated With HIV-1 Disease Progression.. <i>Frontiers in Immunology</i> , <b>2021</b> , 12, 811091	8.4	3
47	Boosting viral-specific immunotherapy for chronic hepatitis B treatment. <i>Cellular and Molecular Immunology</i> , <b>2021</b> , 18, 2586-2587	15.4	
46	Human mesenchymal stem cells treatment for severe COVID-19: 1-year follow-up results of a randomized, double-blind, placebo-controlled trial.. <i>EBioMedicine</i> , <b>2021</b> , 75, 103789	8.8	9
45	COVID-19 immune features revealed by a large-scale single-cell transcriptome atlas. <i>Cell</i> , <b>2021</b> , 184, 1895-1913	56.1	1519
44	Changes of Damage Associated Molecular Patterns in COVID-19 Patients. <i>Infectious Diseases &amp; Immunity</i> , <b>2021</b> , 1, 20-27		2
43	HLA-mismatched allogeneic adoptive immune therapy in severely immunosuppressed AIDS patients. <i>Signal Transduction and Targeted Therapy</i> , <b>2021</b> , 6, 174	21	0
42	Compromised long-lived memory CD8 T cells are associated with reduced IL-7 responsiveness in HIV-infected immunological nonresponders. <i>European Journal of Immunology</i> , <b>2021</b> , 51, 2027-2039	6.1	1
41	Human umbilical cord mesenchymal stem cell transfusion in immune non-responders with AIDS: a multicenter randomized controlled trial. <i>Signal Transduction and Targeted Therapy</i> , <b>2021</b> , 6, 217	21	1
40	A multi-omics investigation of the composition and function of extracellular vesicles along the temporal trajectory of COVID-19. <i>Nature Metabolism</i> , <b>2021</b> , 3, 909-922	14.6	24
39	Diagnosis and Treatment Guidelines for Mesenchymal Stem Cell Therapy for Coronavirus Disease 2019 (Beijing, 2021). <i>Infectious Diseases &amp; Immunity</i> , <b>2021</b> , 1, 68-73		1
38	Single-Cell Transcriptomic Profiling of MAIT Cells in Patients With COVID-19. <i>Frontiers in Immunology</i> , <b>2021</b> , 12, 700152	8.4	6
37	Neutrophils in liver diseases: pathogenesis and therapeutic targets. <i>Cellular and Molecular Immunology</i> , <b>2021</b> , 18, 38-44	15.4	20
36	Host-directed therapies for COVID-19. <i>Current Opinion in Pulmonary Medicine</i> , <b>2021</b> , 27, 205-209	3	1

35	Effect of human umbilical cord-derived mesenchymal stem cells on lung damage in severe COVID-19 patients: a randomized, double-blind, placebo-controlled phase 2 trial. <i>Signal Transduction and Targeted Therapy</i> , <b>2021</b> , 6, 58	21	70
34	Granulocyte-macrophage colony-stimulating factor: an immunotarget for sepsis and COVID-19. <i>Cellular and Molecular Immunology</i> , <b>2021</b> , 18, 2057-2058	15.4	1
33	Increased Neutrophil Aging Contributes to T Cell Immune Suppression by PD-L1 and Arginase-1 in HIV-1 Treatment Naïve Patients. <i>Frontiers in Immunology</i> , <b>2021</b> , 12, 670616	8.4	0
32	Mesenchymal stem cell therapy for severe COVID-19. <i>Signal Transduction and Targeted Therapy</i> , <b>2021</b> , 6, 339	21	10
31	Immune restoration in HIV-1-infected patients after 12 years of antiretroviral therapy: a real-world observational study. <i>Emerging Microbes and Infections</i> , <b>2020</b> , 9, 2550-2561	18.9	9
30	Omics-Driven Systems Interrogation of Metabolic Dysregulation in COVID-19 Pathogenesis. <i>Cell Metabolism</i> , <b>2020</b> , 32, 188-202.e5	24.6	199
29	Persistent Viral Presence Determines the Clinical Course of the Disease in COVID-19. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , <b>2020</b> , 8, 2585-2591.e1	5.4	28
28	An immunopathogenic perspective of interleukin-1 signaling. <i>Cellular and Molecular Immunology</i> , <b>2020</b> , 17, 892-893	15.4	2
27	Expansion of myeloid-derived suppressor cells in patients with severe coronavirus disease (COVID-19). <i>Cell Death and Differentiation</i> , <b>2020</b> , 27, 3196-3207	12.7	115
26	Liver injury in COVID-19: management and challenges. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2020</b> , 5, 428-430	18.8	1048
25	Immunological and inflammatory profiles in mild and severe cases of COVID-19. <i>Nature Communications</i> , <b>2020</b> , 11, 3410	17.4	186
24	What to do next to control the 2019-nCoV epidemic?. <i>Lancet, The</i> , <b>2020</b> , 395, 391-393	40	139
23	Pathological findings of COVID-19 associated with acute respiratory distress syndrome. <i>Lancet Respiratory Medicine</i> , <b>2020</b> , 8, 420-422	35.1	4985
22	272 Use of LioCyx-M, autologous hepatitis B virus (HBV)-Specific T cell receptor (TCR) T-cells, in advanced HBV-related hepatocellular carcinoma (HCC) <b>2020</b> , 8, A297-A297		2
21	Characteristics and prognostic factors of disease severity in patients with COVID-19: The Beijing experience. <i>Journal of Autoimmunity</i> , <b>2020</b> , 112, 102473	15.5	122
20	A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity. <i>Nature</i> , <b>2020</b> , 586, 572-577	50.4	348
19	Host tolerance contributes to persistent viral shedding in COVID-19. <i>EClinicalMedicine</i> , <b>2020</b> , 26, 100529	11.3	3
18	Effect of combination treatment based on interferon and nucleos(t)ide analogues on functional cure of chronic hepatitis B: a systematic review and meta-analysis. <i>Hepatology International</i> , <b>2020</b> , 14, 958-972	8.8	4

17	A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2. <i>Nature</i> , <b>2020</b> , 584, 120-124	124	844
16	Single-cell landscape of immunological responses in patients with COVID-19. <i>Nature Immunology</i> , <b>2020</b> , 21, 1107-1118	19.1	230
15	Antihypertensive drugs are associated with reduced fatal outcomes and improved clinical characteristics in elderly COVID-19 patients. <i>Cell Discovery</i> , <b>2020</b> , 6, 77	22.3	32
14	Human umbilical cord-derived mesenchymal stem cell therapy in patients with COVID-19: a phase 1 clinical trial. <i>Signal Transduction and Targeted Therapy</i> , <b>2020</b> , 5, 172	21	130
13	High levels of circulating GM-CSFCD4 T cells are predictive of poor outcomes in sepsis patients: a prospective cohort study. <i>Cellular and Molecular Immunology</i> , <b>2019</b> , 16, 602-610	15.4	26
12	Dichotomous Roles of Programmed Cell Death 1 on HIV-Specific CXCR5 and CXCR5 CD8 T Cells during Chronic HIV Infection. <i>Frontiers in Immunology</i> , <b>2017</b> , 8, 1786	8.4	16
11	Low expression of CXCR1/2 on neutrophils predicts poor survival in patients with hepatitis B virus-related acute-on-chronic liver failure. <i>Scientific Reports</i> , <b>2016</b> , 6, 38714	4.9	16
10	The role of neutrophils in the development of liver diseases. <i>Cellular and Molecular Immunology</i> , <b>2014</b> , 11, 224-31	15.4	147
9	Risk factors for liver-related mortality in chronic hepatitis C patients: a deceased case-living control study. <i>World Journal of Gastroenterology</i> , <b>2014</b> , 20, 5519-26	5.6	6
8	The global burden of liver disease: the major impact of China. <i>Hepatology</i> , <b>2014</b> , 60, 2099-108	11.2	734
7	Impairment of CD4+ cytotoxic T cells predicts poor survival and high recurrence rates in patients with hepatocellular carcinoma. <i>Hepatology</i> , <b>2013</b> , 58, 139-49	11.2	109
6	Safety and immunological responses to human mesenchymal stem cell therapy in difficult-to-treat HIV-1-infected patients. <i>Aids</i> , <b>2013</b> , 27, 1283-93	3.5	55
5	Human mesenchymal stem cell transfusion is safe and improves liver function in acute-on-chronic liver failure patients. <i>Stem Cells Translational Medicine</i> , <b>2012</b> , 1, 725-31	6.9	221
4	Immunopathogenesis and prognostic immune markers of chronic hepatitis B virus infection. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2012</b> , 27, 223-30	4	49
3	Hypercytolytic activity of hepatic natural killer cells correlates with liver injury in chronic hepatitis B patients. <i>Hepatology</i> , <b>2011</b> , 53, 73-85	11.2	115
2	PD-1 up-regulation is correlated with HIV-specific memory CD8+ T-cell exhaustion in typical progressors but not in long-term nonprogressors. <i>Blood</i> , <b>2007</b> , 109, 4671-8	2.2	233
1	Treatment with human umbilical cord-derived mesenchymal stem cells for COVID-19 patients with lung damage: a randomised, double-blind, placebo-controlled phase 2 trial		1